NRG-GU003 Trial Compares Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Prostate Cancer
Five-year results from the Phase III NRG-GU003 clinical trial demonstrate that hypofractionated postprostatectomy radiotherapy (HYPORT)—delivering a shorter 25-fraction course of radiation—achieves biochemical control and patient-reported quality-of-life outcomes comparable to conventional … Read More